Virpax Pharmaceuticals engages Destum to serve as exclusive advisor

Virpax Pharmaceuticals announced that the Company has engaged Destum Partners to serve as the exclusive advisor for the Company’s partnering and licensing efforts in strategic global markets. This initial engagement will encompass the Company’s two over-the-counter product candidates, Epoladerm, indicated for osteoarthritis pain, and AnQlar, an intranasal mucosal viral barrier. Additionally, Destum Partners will work with Virpax on identifying a partner in the animal health market for its Rx product candidate, Probudur, a long-acting local anesthetic indicated for postoperative pain management. "We have engaged Destum Partners to lead our global strategic partnering and licensing efforts for our two potential OTC product candidates as well as supporting Virpax in the animal health care market for Probudur," stated Anthony Mack, Chairman and CEO of Virpax. "While we have continued to pursue potential transactions with pharmaceutical companies for all of these product candidates, we believe that to maximize value for the Company and our shareholders we would be best served by partnering with a firm that has this type of transactional experience."